Although clinical trials targeting KSR1 have yet to be initiated, clinical studies to target the RAS/MAPK signaling cascade at multiple levels in various cancers could inform the therapeutic effect of targeting KSR1 in human cancers, including HCC. The gene discussed is KSR1; the disease is hepatocellular carcinoma.